{"title": "ESC 2021: Bayer's Kerendia touts outcomes data as it looks to complement J&J, AZ drugs", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/pharma/a-month-after-its-initial-approval-kerendia-shows-its-worth-as-a-complementary-treatment", "hostname": "fiercepharma.com", "description": "When Bayer unveiled early-stage results from a finerenone trial at the European Society of Cardiology Congress in 2014, the company declared it was going all in on the kidney disease drug. | Bayer's chronic kidney disease drug Kerendia totted up kidney and cardiovascular outcomes wins in two massive trials at the European Society of Cardiology Congress on Saturday. While its efficacy figures fall short of rivals such as AstraZeneca's Farxiga and Johnson & Johnson's Invokana, Bayer believes Kerendia can add its own benefits.", "sitename": "FiercePharma", "date": "2021-08-28", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}